Skip Navigation
Skip to contents

Ann Coloproctol : Annals of Coloproctology

OPEN ACCESS
SEARCH
Search

Page Path
HOME > Browse Articles
Search
Kyung Ook Jung 1 Article
Oncologic Outcomes of Stage IIIA Colon Cancer for Different Chemotherapeutic Regimens
Yoo Sung Lee, Hee Cheol Kim, Kyung Ook Jung, Yong Beom Cho, Seong Hyeon Yun, Woo Yong Lee, Ho-Kyung Chun
J Korean Soc Coloproctol. 2012;28(5):259-264.   Published online October 31, 2012
DOI: https://doi.org/10.3393/jksc.2012.28.5.259
  • 4,076 View
  • 12 Download
  • 2 Citations
AbstractAbstract PDF
Purpose

Adjuvant chemotherapy is currently recommended for Stage IIIA colon cancers. This study aimed to elucidate the oncologic outcomes of Stage IIIA colon cancer according to the chemotherapeutic regimen based on a retrospective review.

Methods

From 1995 to 2008, Stage IIIA colon cancer patients were identified from a prospectively maintained database at a single institution. Exclusion criteria were as follows: rectal cancer, another malignancy other than colon cancer, no adjuvant chemotherapy and unknown chemotherapeutic regimen. One hundred thirty-one patients were enrolled in the study, and the clinicopathologic and the oncologic characteristics were analyzed. The number of males was 72, and the number of females was 59; the mean age was 59.5 years (range, 25 to 76 years), and the median follow-up period was 33 months (range, 2 to 127 months).

Results

Of the 131 patients, fluorouracil/leucovorin (FL)/capecitabine chemotherapy was performed in 109 patients, and FOLFOX chemotherapy was performed in 22 patients. When the patients who received FL/capecitabine chemotherapy and the patients who received FOLFOX chemotherapy were compared, there was no significant difference in the clinicopathologic factors between the two groups. The 5-year overall survival and the 5-year disease-free survival were 97.2% and 94.5% in the FL/capecitabine patient group and 95.5% and 90.9% in the FOLFOX patient group, respectively, and no statistically significant differences were noted between the two groups.

Conclusion

Stage IIIA colon cancer showed good oncologic outcomes, and the chemotherapeutic regimen did not seem to affect the oncologic outcome.

Citations

Citations to this article as recorded by  
  • A New Method for Constructing Macrophage-Associated Predictors of Treatment Efficacy Based on Single-Cell Sequencing Analysis
    Jianxiu Lin, Yang Ran, Tengfei Wu, Zishan Wang, Jinjin Zhao, Yun Tian
    Journal of Immunotherapy.2024; 47(2): 33.     CrossRef
  • Distinctive oncological features of stage IIIA colorectal cancer: Analysis of prognostic factors for selective adjuvant chemotherapy
    Soo Yeun Park, Gyu‐Seog Choi, Jun Seok Park, Hye Jin Kim, Yoshiharu Sakai, Suguru Hasegawa, Toshiaki Watanabe, Seon Hahn Kim
    Journal of Surgical Oncology.2015; 111(7): 882.     CrossRef

Ann Coloproctol : Annals of Coloproctology Twitter Facebook
TOP